Kiyatec Announces Enrollment of First Patients in Clinical Trial to Predict Personalized Response to Oncology Drugs Prior to Treatment businesswire.com/news/home/2018…

Sending our congratulations to the new Miss North Carolina, and Gibbons alum, Laura Matrazzo '13. Wishing you the best as you represent North Carolina in the coming year! Laura Matrazzo

This latest financing will enable us to continue to build our clinical development program for #RaDaR, bringing its benefits to patients directly: bit.ly/3re69d0 We are pleased to be a step closer to transforming the lives of patients on this #worldcancerday2021

Our new funding will accelerate clinical development of the RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung...

🧬🧪 In two studies at #AACR2021, our #RaDaR #MRD assay demonstrated excellent specificity (100%) and sensitivity (100%) in patient cohorts with head and neck cancer and early-stage breast cancer…

…In a retrospective breast cancer study, RaDaR identified MRD in 100% of relapsed patients and in 0% of the patients that did not relapse. This included patients with brain-only metastasis 🧠 which was not previously achievable with single mutation dPCR MRD-detection assays…

…Meanwhile preliminary data from the LIONESS 🦁 study in head and neck cancer also shows 100% ctDNA detection at levels as low as 0.0006% VAF …

On Saturday we shared new data on our #RaDaR #MRD assay and InVisionFirst-Lung #LiquidBiopsy test at #AACR2021 RaDaR demonstrated excellent specificity (100%) and sensitivity (100%) in two new studies in head and neck cancer and early-stage breast cancer: bit.ly/3mCttjj

Our acquisition by NeoGenomics follows a $25 million minority equity investment in #Inivata in May 2020, at which the Company was granted a fixed price option to purchase the remainder of #Inivata for $390 million. Learn more here: bit.ly/3aZAfen

#RaDaR™ supports the work of our #biopharma partners across multiple applications, optimizing #clinicaltrials and accelerating precision #oncology drug development. Discover the value of RaDaR™ for our #partners here: inivata.com/radar-biopharm…

Molecular residual disease (#MRD) refers to traces of #cancer that may remain in a patient’s body even after #treatment. This may only be present at very low levels and left unrecognized, this may eventually cause the cancer to come back. bit.ly/3DcBi6q

We’re pleased to have been shortlisted for ‘Best Established #Medtech’ at the #OBNAwards2021, taking place on Thursday 25th November. Thank you OBN_UK for recognizing the quality of our #liquidbiopsy technology in transforming cancer #diagnostics and care obn-awards.com

How lucky I am to work with and be guided by an exceptional role model Stephanie Downs-Canner

Patients are at the heart of everything we do. Today and everyday #WorldCancerDay #transformingcancercare #liquidbiopsy

Happy #InternationalWomensDay to all our inspiring women partners, physicians and patients. We are transforming clinical cancer care - together #liquidbiospy #invision

Inivata Publishes Results of Analytical Validation for InVisionFirst-Lung ctDNA Liquid Biopsy inivata.com/inivata-publis… #invision #liquidbiopsy #transformingcancercare

New publication available on our website - Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. doi.org/10.1371/journa… #invision #liquidbiopsy

New publication support robustness and reproducibility of the InVision™ platform. Industry-leading sensitivity and specificity shown across all classes of genomic alterations relevant to non-small cell lung cancer journals.plos.org/plosone/articl…

(1/2) Join us for the first presentation at #AACR18 on how #ctDNA sequencing could be a complementary, non-invasive tool to monitor responses to treatment & mechanisms of resistance in NSCLC patients treated with EGFR inhibitors

(1/2) Also, come and watch a presentation of the results of an analytical validation study using InVision, our NGS-based assay offering broad molecular profiling with exceptional #sensitivity for analysis of #ctDNA #AACR18